CRISPR-Engineered immune cells target advanced lung cancer
Disease control
Terminated
This trial aimed to test a new cell therapy for metastatic non-small cell lung cancer. It planned to use a patient's own tumor-fighting immune cells, genetically edited with CRISPR technology to remove a molecular 'brake' called CISH. The goal was to see if these supercharged cel…
Phase: PHASE1, PHASE2 • Sponsor: Intima Bioscience, Inc. • Aim: Disease control
Last updated Mar 23, 2026 15:17 UTC